Bufuralol

Bufuralol
Names
	Preferred IUPAC name 2-(tert-Butylamino)-1-(7-ethyl-1-benzofuran-2-yl)ethan-1-ol
	Other names 2-(tert-Butylamino)-1-(7-ethylbenzofuran-2-yl)ethan-1-ol; 2-(tert-Butylamino)-1-(7-ethyl-1-benzofuran-2-yl)ethanol
Identifiers
CAS Number	54340-62-4 ;
3D model (JSmol)	Interactive image;
ChEMBL	ChEMBL296035;
ChemSpider	64777;
ECHA InfoCard	100.053.720
PubChem CID	71733;
UNII	891H89GFT4;
CompTox Dashboard (EPA)	DTXSID30866414 ;
	InChI InChI=1S/C16H23NO2/c1-5-11-7-6-8-12-9-14(19-15(11)12)13(18)10-17-16(2,3)4/h6-9,13,17-18H,5,10H2,1-4H3;
	SMILES OC(c2oc1c(cccc1c2)CC)CNC(C)(C)C;
Properties
Chemical formula	C16H23NO2
Molar mass	261.365 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

Bufuralol is a potent beta-adrenoceptor antagonist with partial agonist activity.^[1] It is metabolized by CYP2D6.^[2]

Most beta blockers are aryloxypropanolamine-based. In this rare exception, the benzofuran oxygen is part of a ring instead of derived from the epichlorohydrin precursor.

References

^ Pringle, TH; Francis, RJ; East, PB; Shanks, RG (1986). "Pharmacodynamic and pharmacokinetic studies on bufuralol in man". British Journal of Clinical Pharmacology. 22 (5): 527–34. doi:10.1111/j.1365-2125.1986.tb02931.x. PMC 1401192. PMID 2878678.
^ Flockhart DA (2007). "Drug Interactions: Cytochrome P₄₅₀ Drug Interaction Table". Indiana University School of Medicine. Retrieved on July 2011

This drug article relating to the cardiovascular system is a stub. You can help Wik.ipedia.Pro by expanding it.

[1] Pringle, TH; Francis, RJ; East, PB; Shanks, RG (1986). "Pharmacodynamic and pharmacokinetic studies on bufuralol in man". British Journal of Clinical Pharmacology. 22 (5): 527–34. doi:10.1111/j.1365-2125.1986.tb02931.x. PMC 1401192. PMID 2878678.

[Flockhart-2] Flockhart DA (2007). "Drug Interactions: Cytochrome P₄₅₀ Drug Interaction Table". Indiana University School of Medicine. Retrieved on July 2011

[1]

[2]

Bufuralol

References

See what we do next...

OR